CD22, CD22 molecule, 933

N. diseases: 106; N. variants: 6
Disease: Refractory Adult Acute Lymphoblastic Leukemia ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C4288302
Disease: Refractory Adult Acute Lymphoblastic Leukemia
Refractory Adult Acute Lymphoblastic Leukemia 		0.030 Biomarker disease BEFREE Immunotherapies targeting CD19 (blinatumomab) and CD22 (inotuzumab ozogamicin) have demonstrated higher complete response rates and improved survival compared with chemotherapy in relapsed/refractory acute lymphoblastic leukemia (ALL), and are now standard of care in the relapsed setting. 31766014 2019
CUI: C4288302
Disease: Refractory Adult Acute Lymphoblastic Leukemia
Refractory Adult Acute Lymphoblastic Leukemia 		0.030 Biomarker disease BEFREE Chimeric antigen receptor T-cell (CART) therapy targeting CD22 induces remission in 70% of patients with relapsed/refractory acute lymphoblastic leukemia (ALL). 31110075 2019
CUI: C4288302
Disease: Refractory Adult Acute Lymphoblastic Leukemia
Refractory Adult Acute Lymphoblastic Leukemia 		0.030 Biomarker disease BEFREE We examined treatment with sequential infusion of humanized CD19-modified and CD22-modified CAR-T cells in a patient with relapsed ALL previously exposed to murine-derived anti-CD19 CAR-T cells. 30988623 2019